Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced that its subsidiary, Yaopharma Co., Ltd., has secured marketing registration approval from the National Medical Products Administration for a new drug, Nicorandil for Injection, aimed at treating unstable angina pectoris. The approval marks a significant milestone for the company, ensuring that the self-developed medication can be brought to market. This development could potentially impact the company’s stock as it represents a noteworthy advancement in its pharmaceutical offerings.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
